<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562133</url>
  </required_header>
  <id_info>
    <org_study_id>APIDR_L_01896</org_study_id>
    <secondary_id>EudraCT Number 2006-005127-42</secondary_id>
    <nct_id>NCT00562133</nct_id>
  </id_info>
  <brief_title>Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes</brief_title>
  <official_title>Effect of Prandial Treatment With Insulin Glulisine Compared to Regular Human Insulin on Postprandial Endothelial Function and Microvascular Stress in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IKFE Institute for Clinical Research and Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IKFE Institute for Clinical Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the postprandial time course of&#xD;
      nitrotyrosine after injection of insulin glulisine compared with regular human insulin.&#xD;
&#xD;
      The secondary objectives are to evaluate the postprandial time course of the following&#xD;
      efficacy parameters after injection of insulin glulisine compared with regular insulin on&#xD;
&#xD;
        -  Blood Glucose&#xD;
&#xD;
        -  Insulin&#xD;
&#xD;
        -  Intact proinsulin&#xD;
&#xD;
        -  Asymmetric dimethylarginine (ADMA)&#xD;
&#xD;
        -  Metal matrix proteasis (MMP-9)&#xD;
&#xD;
        -  Oxidative status (per ox)&#xD;
&#xD;
        -  Interleukin 18 (IL-18)&#xD;
&#xD;
        -  Free fatty acids (FFA)&#xD;
&#xD;
        -  Oxidised LDL (ox-LDL)&#xD;
&#xD;
        -  Microvascular blood circulation measured with laser Doppler at 37 °C (LDF37)&#xD;
&#xD;
        -  Microvascular blood circulation measured with laser Doppler at 44 °C (LDF44)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III b Indication Type 2 Diabetes Trial Objectives 1) Primary objective: The primary&#xD;
      objective of the study is to evaluate the postprandial time course of nitrotyrosine after&#xD;
      injection of insulin glulisine compared with regular human insulin. 2) Secondary objectives:&#xD;
      The secondary objectives are to evaluate the postprandial time course of blood glucose,&#xD;
      insulin, intact proinsulin, asymmetric dimethylarginine (ADMA), metal matrix proteasis&#xD;
      (MMP-9), free fatty acids (FFA), oxidised LDL (ox-LDL), oxidative status (per ox), IL-18 as&#xD;
      well as postprandial time course of microvascular blood circulation measured with&#xD;
      laserdopplerflux at 37 °C (LDF37) and 44 C (LDF44).&#xD;
&#xD;
      Efficacy Variables Primary efficacy variablePostprandial time course of&#xD;
      nitrotyrosineSecondary efficacy variablePostprandial time course of glucose, insulin, intact&#xD;
      proinsulin, ADMA, MMP-9, FFA, ox-LDL, per-ox, and IL-18 as well as postprandial time course&#xD;
      of laserdopplerflux at 37 °C and 44 °C Safety Variables Incidence and frequency of adverse&#xD;
      events and evaluation of safety laboratory parameters Medication/Dosage Insulin glulisine,&#xD;
      dose 0.10 U/kg and Regular Human Insulin, dose 0.10 U/kg Study Duration Duration of study&#xD;
      participation for one patient: 5 - 43 days Overall duration of the study: 6 months Design&#xD;
      Single-centre, open label, randomized, 2-way-crossover trial Population Male and female type&#xD;
      2 diabetic patients between 40 and 70 years with HbA1c between 6.5 % and 9.9 % and treated&#xD;
      with sulfonyurea alone or in combination with Metformin in a stable dosage within the last 3&#xD;
      months Sample Size N = 15&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the postprandial time course of nitrotyrosine after injection of insulin glulisine compared with regular human insulin</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>postprandial time course of blood glucose, insulin, intact proinsulin, ADMA, MMP-9, FFA, ox-LDL, per ox Status, IL-18, postprandial time course of microvascular blood circulation measured with laserdopplerflux at 37 °C and 44 C</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Day Treatment with Insulin Glulisine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One day Treatment with Human insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Insuman</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 2 Diabetes mellitus according to the ADA criteria&#xD;
&#xD;
          2. HbA1c between 6.5 % and 9.9 %&#xD;
&#xD;
          3. Monotherapy with sulfonylurea or combined with Metformin in a stable dosage within the&#xD;
             last 3 months&#xD;
&#xD;
          4. Age between 40 and 70 years&#xD;
&#xD;
          5. BMI &lt; 40&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 Diabetes mellitus&#xD;
&#xD;
          2. Pre-Treatment with insulin within the last 6 months prior to screening&#xD;
&#xD;
          3. Treatment with glitazones within the last 6 months prior to screening&#xD;
&#xD;
          4. Pre-Treatment with PPARy-agonists, glinides or glucosidase inhibitors within the last&#xD;
             4 weeks prior to screening&#xD;
&#xD;
          5. Untreated hypertension stage II-III according to WHO criteria&#xD;
&#xD;
          6. Planned or anticipated change in antidiabetic and/or concomitant medication during&#xD;
             study participation&#xD;
&#xD;
          7. Total Cholesterol &gt; 300 mg/dl (anamnestically)&#xD;
&#xD;
          8. Hypokalemia (K &lt; 3.5 mmol /l)&#xD;
&#xD;
          9. Major micro- or macrovascular complications as judged by the investigator&#xD;
&#xD;
         10. Tobacco use within the last 12 months prior to screening&#xD;
&#xD;
         11. Drugs with major impact on endothelial function like nitrates etc.&#xD;
&#xD;
         12. History of drug or alcohol abuse within the last five years prior to screening&#xD;
&#xD;
         13. Anamnestic history of hypersensitivity to the study drugs or to drugs with similar&#xD;
             chemical structures&#xD;
&#xD;
         14. History of severe or multiple allergies&#xD;
&#xD;
         15. Treatment with any other investigational drug within 3 months prior to screening&#xD;
&#xD;
         16. Progressive fatal disease&#xD;
&#xD;
         17. History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT&#xD;
             and/or ASAT &gt; 3 times the normal reference range), renal (creatinine &gt; 1.1 mg/dL in&#xD;
             women, &gt; 1.5 mg/dL in men), neurological, psychiatric and/or haematological disease as&#xD;
             judged by the investigator&#xD;
&#xD;
         18. Pregnancy or breast feeding&#xD;
&#xD;
         19. Sexually active women of childbearing potential not consistently and correctly&#xD;
             practicing birth control by implants, injectables, combined oral contraceptives,&#xD;
             hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner&#xD;
&#xD;
         20. Lack of compliance or other similar reason, that according to investigator, precludes&#xD;
             satisfactory participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A Forst, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Clinical Research and Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ikfe</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <last_update_submitted>November 20, 2007</last_update_submitted>
  <last_update_submitted_qc>November 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2007</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

